World IBD Day

May 19 is World IBD Day.

Inflammatory bowel disease (IBD) is a chronic, relapsing, progressive immune-mediated condition, primarily including Crohn’s disease and ulcerative colitis. Beyond persistent intestinal inflammation, patients often face long-term challenges including abdominal pain, fatigue, malabsorption, relapse, and psychological burden.

The global prevalence of IBD continues to rise, with an increasing trend toward earlier onset. Despite expanding treatment options, significant unmet needs remain: limited response in some patients, long-term safety challenges, and room for improvement in disease modification and durable mucosal healing.

These challenges highlight that IBD is not merely an inflammatory disease but also a long-term medical challenge. Consequently, increasing research is focusing on the role of immunometabolism in autoimmune diseases. Dysregulated immune cell metabolism is considered closely linked to persistent inflammation, immune imbalance, and disease progression, offering new directions for next-generation therapeutic strategies.

Meta Bio has long focused on innovative drug discovery in immunometabolism, committed to exploring novel intervention pathways for autoimmune and metabolic diseases.

MP-5342, the company’s lead pipeline candidate, is an oral small molecule targeting lactate dehydrogenase (LDH), with IBD as its primary indication. As one of the world’s first highly selective oral LDH small molecule inhibitors, MP-5342 aims to restore immune balance by modulating aberrant immune cell metabolism, exploring disease-modifying therapeutic potential from the underlying mechanism.

From disease understanding to therapeutic evolution, many questions in IBD remain to be explored. On World IBD Day, Meta Bio hopes to join patients, physicians, researchers, and industry partners in focusing on persistent unmet clinical needs, advancing translation from basic science to clinical value, and bringing new therapeutic possibilities for autoimmune diseases.